18 October 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC on 15-16 February 2024.

The agenda currently has 13 items. Applications of note include:

• 1686.1– Lutetium Lu 177 PSMA for metastatic castrate resistant prostate cancer
• 1720 – Gallium Ga 68 PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy
• 1722.1 – Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Read MSAC agenda